Suchergebnisse - "Tabernero, J"

PubPharm (32)

1

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

enthalten in: ESMO open | 2022

von Borazanci, E. | Schram, A. | Garralda, E. | +20

2

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer : patient-reported outcomes from BEACON CRC

enthalten in: ESMO open | 2022

von Kopetz, S. | Grothey, A. | Van Cutsem, E. | +14

3

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors : first-in-human dose-escalation study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Gazzah, A. | Bedard, P. | Hierro, C. | +9

4

BRAF mutant colorectal cancer : prognosis, treatment, and new perspectives

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Sanz-Garcia, E. | Argiles, G. | Elez, E. | +1

5

Pancreatic cancer heterogeneity and response to Mek inhibition

enthalten in: Oncogene | 2017

von Pedersen, K. | Bilal, F. | Bernadó Morales, C. | +14

6

Targeting the fibroblast growth factor receptor 2 in gastric cancer : promise or pitfall?

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Hierro, C. | Alsina, M. | Sánchez, M. | +3

ErratumIn: Ann Oncol. 2018 Jul 1;29(7):1605. - PMID 29300805

7

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours : the CLARINET open-label extension study

enthalten in: Endocrine-related cancer | 2016

von Caplin, M. | Pavel, M. | Ćwikła, J. | +66

8

Optimising translational oncology in clinical practice : strategies to accelerate progress in drug development

enthalten in: Cancer treatment reviews | 2015

von Stahel, R. | Bogaerts, J. | Ciardiello, F. | +12

9

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer : the randomised phase I/II POSEIDON trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Élez, E. | Kocáková, I. | Höhler, T. | +14

10

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer : a randomized phase II study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Van Cutsem, E. | Boni, C. | Tabernero, J. | +17